Depomed shares boosted on marketing app for DM-1796; Genzyme names its first COO;

 @FierceBiotech: New Boehringer fund to invest $135M in biotech, start-ups. Report | Follow @FierceBiotech

 @JohnCFierce: Two things to highlight on this Glaxo/Isis deal. Glaxo is showing its love of rare diseases, and Isis gets marks for staying in control to proof-of-concept. | Follow @JohnCFierce

> Shares of Depomed were buoyed by the news that the developer has filed for marketing approval of its new neuropathic pain med. DM-1796 is an oral version of gabapentin, a therapy used to treat seizures and PHN. Report

> In advance of an FDA enforcement action regarding its troubled Allston facility, Genzyme has named Executive Vice President David Meeker to the newly created post of chief operating office. The new position and appointment is intended to "establish a sharper focus on commercial execution." Genzyme release

> Astellas has extended its tender offer for shares of OSI Pharmaceuticals, which is an expected part of the truce the two companies established recently. Report

> Biotech places second in InformationWeek's salary survey among highest-paying industries for U.S. IT managers. Story

> GlaxoSmithKline has won European approval of Duodart, a combo prostate drug that matches its Avodart with Astellas' dutasteride. Story

> Melior Discovery it has entered into a collaboration with the Rett Syndrome Research Trust to screen drug-candidates in an in vivo model of Rett Syndrome. Melior release

> GeoVax Labs has been given a green light to start an early-stage trial of an HIV therapy. Story

And Finally... Blocking the cellular signaling activity of a protein prevented memory loss in fruit flies caused by brain plaques similar to those thought to cause Alzheimer's disease in humans. Report

Suggested Articles

Inovio CEO J. Joseph Kim is undeterred by short sellers and other detractors who doubt his company can shuttle a COVID-19 DNA vaccine to market.

Adding entinostat to hormone therapy did not help patients with HR-positive, HER2-negative breast cancer live longer.

The data add to the evidence in support of the IL-6 drug ahead of a FDA decision to approve it in a rare disease served by Alexion’s Soliris.